

SUPPLEMENTARY TABLE S3		Differences over time on characteristics of 153 LT patients readmitted to 5 ICUs in Spain.					
Year		2012	2013	2014	2015	2016	P value
Nº patients		15	48	42	33	15	-
Age		56 [43-63]	56 [42.8-59.2]	60.5 [52.5-63.8]	58 [53.-63]	61 [56.5-66]	0.01
Gender ^m		12 (80)	39 (81.3)	31 (73.8)	14 (42.4)	9 (60)	0.8
Pre-transplant lung disease							
IPF		6 (40)	18 (37.4)	15 (35.6)	14 (42.5)	8 (53.3)	
COPD		5 (33.3)	15 (31.3)	18 (42.9)	8 (24.2)	5 (33.3)	
Cystic fibrosis		1 (6.7)	7 (14.6)	1 (2.4)	3 (9.1)	0	
DILD		0	0	4 (9.5)	3 (9.1)	1 (6.7)	
Bronchiectasis		1 (6.7)	1 (2.1)	2 (4.8)	1 (3)	1 (6.7)	
Pulmonary hypertension		0	1 (2.1)	2 (4.8)	1 (3)	0	
Other ^a		2 (13.3)	6 (12.5)	0	3 (9.1)	0	
Type of LT							
Bilateral		9 (60)	27 (56.3)	26 (61.9)	14 (42.4)	6 (40)	
Left		4 (26.7)	12 (25)	10 (23.8)	10 (30.3)	4 (26.6)	
Right		2 (13.3)	9 (18.7)	6 (14.3)	9 (27.3)	5 (33.4)	
History of early^b complications after LT⁺							
Phrenic paresis		2 (13.3)	8 (16.7)	15 (35.7)	13 (39.4)	2 (13.3)	0.08
PGD		2 (13.3)	11 (22.9)	9 (21.4)	9 (27.3)	2 (13.3)	0.9
AKI		3 (20)	6 (12.5)	9 (21.4)	8 (24.2)	1 (6.7)	0.3
Pneumonia		2 (13.3)	10 (20.8)	4 (9.5)	4 (12.1)	2 (13.3)	0.6
Gastroparesis		5 (33.4)	7 (14.6)	9 (21.4)	5 (15.2)	1 (6.7)	0.6
Tracheobronchitis		0	3 (6.3)	6 (14.3)	5 (15.2)	2 (13.3)	0.5
Haemorrhage		0	4 (8.9)	5 (11.9)	3 (9.1)	1 (6.7)	0.9
Thrombosis		1 (6.7)	2 (4.2)	5 (11.9)	3 (9.1)	1 (6.7)	0.6
CMV replication		0 ()	3 (6.3)	5 (11.9)	2 (6.1)	0	0.7
Suture stenosis		0 ()	4 (8.3)	0	2 (6.1)	0	0.3
Suture dehiscence		0 ()	1 (2.1)	1 (2.4)	2 (6.1)	0	0.8
History of late complications after LT⁺							
Infection		1 (6.7)	9 (18.7)	14 (33.3)	12 (36.4)	5 (33.3)	0.2
CLAD		4 (26.7)	16 (33.3)	5 (11.9)	6 (18.2)	4 (26.6)	0.06
History of acute rejection episode		4 (26.7)	13 (27.1)	9 (21.4)	3 (9.1)	1 (6.7)	0.06
CKD		3 (20)	12 (25)	7 (16.6)	4 (12.1)	3	0.05
Bronchial stenosis		0	6 (12.5)	6 (14.3)	7 (21.2)	2 (13.3)	0.3
Diabetes mellitus		2 (13.3)	3 (6.3)	8 (19.1)	5 (15.2)	2 (13.3)	0.8
High blood pressure		1 (6.7)	2 (4.2)	2 (4.8)	3 (9.1)	3 (20)	0.2
Osteoporosis		0	0	3 (7.1)	7 (21.2)	1 (6.7)	0.01
Time LT-ICUr,month		3 [2-10]	5.5 [1-18.5]	6[3-24]	9[4-25]	3[1-29.5]	0.1
APACHE II score		18 [14-21]	18.5 [14-27.2]	20.5 [15.2-25.8]	19 [15-24]	22 [16-24]	0.8
SOFA score		4 [2-6]	5.5 [3-9]	4 [3-6.8]	4 [3-8]	6.5 [3.5-10]	0.2
Indication for ICUr							
ARF		13 (86.7)	32 (66.7)	31 (73.8)	25 (75.8)	9 (60)	
Shock		1 (6.7)	3 (6.3)	2 (4.8)	2 (6.1)	1 (6.7)	
Post-operative		0	4 (8.9)	1 (2.4)	2 (6.1)	1 (6.7)	
Neurologic		0	1 (2.1)	2 (4.8)	1 (3)	1 (6.7)	
compromise							
Other ^a		1 (6.7)	8 (16.7)	6 (14.3)	3 (9.1)	3 (20)	
Conditions in patients with ICUr⁺							
Infection		13 (86.7)	29	16 (38.1)	10 (30.3)	7 (46.7)	0.3
Pneumonia		12 (80)	16	13 (40)	9 (27.3)	6 (40)	0.4
Sepsis		1 (6.7)	24	13 (40)	10 (30.3)	7 (46.7)	0.3
Septic Shock		0	18	8 (19.1)	7 (21.2)	4 (26.6)	0.3
Techniques and Support							
IMV requirement		8 (53.3)	35 (72.9)	24 (57.1)	19 (57.6)	9 (60)	0.5

Vasopressor requirement	1 (6.7)	20 (41.7)	8 (19.1)	7 (21.2)	4 (26.6)	0.05
Deaths in ICU	8 (53.3)	21 (43.8)	9 (21.4)	12 (36.4)	5 (33.4)	0.2
Deaths in hospital	9 (60)	26 (54.2%)	14 (33.3)	15 (45.5)	5 (33.4)	0.4

Data are presented as median [Interquartile range (IQR)] or Number/Total (%) unless otherwise indicated.

LT, Lung transplant; IPF, Idiopathic pulmonary fibrosis; COPD, Chronic obstructive pulmonary disease ; DILD, Diffuse interstitial lung disease; PGD, Primary graft dysfunction; AKI, Acute kidney injury; CMV, Cytomegalovirus; CLAD, Chronic lung allograft dysfunction; CKD, Chronic kidney disease; APACHE II, Acute Physiology and Chronic Health Evaluation II; SOFA, Sequential Organ Failure Assessment; ARF, Acute respiratory failure; IMV, Invasive mechanical ventilation.

*Data are presented as median [IQR] or Number (%) proportion of patient per center, unless otherwise indicated.

^mMale gender

[†]Diagnoses are not mutually exclusive.

^aIt encompasses all categories with ≤ 3 patients.

^bImmediate post-operative period